Dataset Information


Paclitaxel-containing high-dose chemotherapy for relapsed or refractory testicular germ cell tumours.

ABSTRACT: High-dose regimes containing etoposide, carboplatin and an oxazaphospharine can salvage 30-40% of patients with relapsed or refractory male germ cell tumours (GCTs). The additional benefit of paclitaxel in such high-dose therapy has not been tested. Between March 1995 and November 2002, 36 male GCT patients were treated with Carbop-EC-T (paclitaxel 75 mg x m(-2), etoposide 450 mg x m(-2), carboplatin AUC 10 on days -7, -5 and -3 and cyclophosphamide 60 mg x kg(-1) on days -5 and -3) followed by peripheral blood stem cell infusion (day 0). The 1-year overall survival rate for all patients is 67% (median follow-up 29 months). For the 24 patients with cisplatin-sensitive disease, the 1-year overall and event-free survivals are 88 and 64%, respectively. For those with cisplatin refractory or absolutely refractory disease, the 1-year overall survival is 25%. In all, 12 patients relapsed at a median duration of 5 months, 11 of whom have died. There were also six treatment-related deaths, five associated with pneumonitis. Pulmonary toxicity has been reported with paclitaxel in other high-dose regimes. Since altering our protocol so that paclitaxel is infused over 24 h with steroid prophylaxis, only one of 18 patients (13 testicular GCTs and five other tumour types) has had a treatment-related death. Our results suggest that Carbop-EC-T may enable a greater proportion of patients with relapsed and refractory GCTs to enter long-term remission.


PROVIDER: S-EPMC2410221 | BioStudies | 2004-01-01

SECONDARY ACCESSION(S): 10.1038/sj.bjc.6601664

REPOSITORIES: biostudies

Similar Datasets

2016-01-01 | S-EPMC5320896 | BioStudies
2015-01-01 | S-EPMC5006186 | BioStudies
2016-01-01 | S-EPMC4827869 | BioStudies
2018-01-01 | S-EPMC6314205 | BioStudies
2010-01-01 | S-EPMC3651604 | BioStudies
2012-01-01 | S-EPMC3494447 | BioStudies
2019-01-01 | S-EPMC6544459 | BioStudies
2003-01-01 | S-EPMC2750619 | BioStudies
2020-01-01 | S-EPMC7177627 | BioStudies
2020-01-01 | S-EPMC7717738 | BioStudies